Navient (NAVI) Q3 2025 Earnings Transcript

Bausch + Lomb reported Q3 revenue of $1.281 billion, up 6% year over year, with adjusted EBITDA rising 7% to $243 million and margin expanding 400 bps sequentially to 19%. Management kept full-year revenue guidance at $5.05 billion-$5.15 billion but raised the low end of adjusted EBITDA guidance to $870 million-$910 million, citing strong execution in Miebo, Xiidra, contact lenses, and a faster-than-expected enVista recovery. Tariffs remain a risk, but the company said 2025 guidance assumes they can be offset.

Analysis

The key signal is not the topline beat; it’s that the company is entering a self-reinforcing phase where mix, not just volume, is doing more of the work. The dry-eye franchise is now large enough that incremental share gains can fund a broader commercial flywheel: stronger coverage, better field productivity, and more leverage on adjacent launches. That matters because the market likely still underestimates how much of the growth is being pulled forward from a category expansion effect rather than simple brand substitution.

The more interesting second-order effect is on the competitive response function. A faster-than-expected recovery in surgical reduces the chance that competitors can permanently harvest share from the recall window, while a sturdier premium IOL mix helps offset pricing pressure elsewhere. In pharma, the company is effectively converting launch spend into a durable installed base, which should make future combination-therapy or next-gen lifitegrast launches cheaper on a per-prescription basis than the street likely models.

The main risk is that the margin story becomes too dependent on temporary operational discipline and favorable mix at a time when exogenous variables remain messy: tariffs, FX, and emerging-market consumer softness can all create noisy quarters. Still, the bigger contrarian point is that guidance may actually be conservative if the enVista recovery and Miebo/Xiidra normalization continue into Q4 and early 2026. The stock should respond more to evidence that SG&A efficiency is structural, not cyclical, because that is what converts a good growth story into a re-rating story.

Key Decisions for Investors

• Long BLCO into the November 13 Investor Day, with a 4-8 week horizon; the setup favors a multiple re-rate if management shows Vision '27 is translating into sustained SG&A leverage and not just quarter-end discipline.
• Add BLCO on dips vs. healthcare peers that lack a clear operating leverage catalyst; risk/reward is attractive if 2026 margin expansion comes through while revenue stays mid-single digit plus.
• Pair trade: long BLCO / short a slower-growth surgical or eye-care peer over the next 1-2 quarters; BLCO has a stronger mix tailwind and a cleaner path to deleveraging if execution holds.
• Buy BLCO call spreads expiring after Investor Day to express upside convexity around the pipeline/margin framework reveal; the main risk is a 'show-me' reaction if details are lighter than expected.
• Avoid shorting on gross margin noise alone; if tariffs and FX are already being offset, near-term downside is more likely from sentiment than fundamentals, making outright bearish exposure unattractive.